{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:22:34Z","timestamp":1792027354813,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ijantimicag.2018.03.008","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T19:13:39Z","timestamp":1521573219000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Population pharmacokinetics of daptomycin in critically ill patients"],"prefix":"10.1016","volume":"52","author":[{"given":"A.","family":"Soraluce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9122-6758","authenticated-orcid":false,"given":"E.","family":"As\u00edn-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Barrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Maynar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Carcelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Soy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-2715","authenticated-orcid":false,"given":"A.","family":"Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijantimicag.2018.03.008_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2018.03.008_bib0002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbamem.2006.02.009","article-title":"Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides","volume":"1758","author":"Straus","year":"2006","journal-title":"Biochim Biohys Acta"},{"issue":"10","key":"10.1016\/j.ijantimicag.2018.03.008_bib0004","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0005","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2018.03.008_bib0006","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ijantimicag.2015.10.009","article-title":"Can we transfer pharmacokinetics\/pharmacodynamics of antimicrobials into clinical practice?","volume":"46","author":"Scaglione","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.03.008_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MCC.0000000000000229","article-title":"Pharmacokinetic\/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill","volume":"21","author":"Tsai","year":"2015","journal-title":"Curr Opin Crit Care"},{"issue":"2","key":"10.1016\/j.ijantimicag.2018.03.008_bib0009","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.orcp.2014.04.001","article-title":"Estimating glomerular filtration rate in obese subjects","volume":"9","author":"Nguyen","year":"2015","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0010","series-title":"NONMEM User's Guides. (1989\u20132009)","author":"Beal","year":"2009"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.03.008_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2013an S-PLUS based population pharmacokinetic\/ pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.03.008_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0013","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine-thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ijantimicag.2018.03.008_bib0015","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s10096-012-1560-7","article-title":"Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries","volume":"31","author":"Canut","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0016","author":"Lavielle"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.03.008_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/ pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.03.008_bib0019","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.ijantimicag.2018.03.008_bib0020","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijantimicag.2018.03.008_bib0021","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.03.008_bib0022","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijantimicag.2013.06.006","article-title":"Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections","volume":"42","author":"Di Paolo","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2018.03.008_bib0023","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.02355-14","article-title":"simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example","volume":"58","author":"Pai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.03.008_bib0024","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","article-title":"Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections","volume":"19","author":"Aikawa","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10156-013-0559-z","article-title":"Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?","volume":"19","author":"Falcone","year":"2013","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.03.008_bib0026","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.02597-15","article-title":"Pharmacokinetic variability of daptomycin during prolonged therapy for bone and joint infections","volume":"60","author":"Goutelle","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.03.008_bib0027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkt342","article-title":"Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment","volume":"69","author":"Chaves","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1159\/000097078","article-title":"Daptomycin clearance during modeled continuous renal replacement therapy","volume":"24","author":"Churchwell","year":"2006","journal-title":"Blood Purif"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0029","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","article-title":"Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis","volume":"39","author":"Vilay","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.5414\/CP201626","article-title":"Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD","volume":"49","author":"Khadzhynov","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.03.008_bib0031","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2018.03.008_bib0032","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"As\u00edn-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.03.008_bib0033","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 26th Edition. M100-S26. CLSI, Wayne, PA, USA, 2016."},{"issue":"1","key":"10.1016\/j.ijantimicag.2018.03.008_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2015.11.005","article-title":"Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data","volume":"47","author":"Senneville","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijantimicag.2018.03.008_bib0036","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2018.03.008_bib0037","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.01011-09","article-title":"Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis","volume":"54","author":"Garc\u00eda-de-la-Mar\u00eda","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T10:44:26Z","timestamp":1561718666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918300797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0924857918300797"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of daptomycin in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}